Stephen K. Tyring

Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study

Psoriasiform mycosis fungoides–cutaneous T-cell lymphoma in an African American

Hemorrhagic herpes zoster duplex unilateralis in a patient taking clopidogrel

A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S)

The Effects of Once-Daily Tretinoin 0.05% Lotion on Quality of Life in Patients with Moderate-to-Severe Acne Vulgaris

Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled study

Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers

Effects of Different Doses of GEN-003, a Therapeutic Vaccine for Genital Herpes Simplex Virus-2, on Viral Shedding and Lesions: Results of a Randomized Placebo-Controlled Trial

Polyomaviruses of the skin: integrating molecular and clinical advances in an emerging class of viruses

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris – A randomized phase II study

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

Helicase–Primase Inhibitor Pritelivir for HSV-2 Infection

Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week results.

Long-term Follow-up Study of Ingenol Mebutate Gel for the Treatment of Actinic Keratoses